About us

The Miyamoto Lab focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate and bladder cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with prostate or bladder cancer.

Do you want to...

Meet current lab members?

Contact the Principal Investigator?

Support our research?

research

Prostate Cancer

is the most common cancer in men and the second leading cause of cancer-related death in men. We discover and develop novel circulating and tissue-based biomarkers to inform clinical decisions in the management of patients with localized and metastatic prostate cancer.

Bladder Cancer

is the fifth most common cancer in the US, causing 18,000 deaths per year. We analyze biospecimens from bladder cancer patients to understand molecular determinants of therapeutic response and discover biomarkers to guide and monitor bladder cancer therapy.

Circulating Tumor Cells (CTCs)

are rare cancer cells shed into the blood stream. CTCs are a type of “liquid biopsy” that can be used to monitor therapy, predict treatment response, and potentially detect cancer early. We have developed microfluidic technologies to efficiently isolate and analyze rare CTCs from blood.

our mission

Improve patient care

Our ultimate goal is to develop molecular tools to guide the personalized and precision care of cancer patients.

Biological discovery

We analyze patient biospecimens to discover mechanisms of cancer progression and treatment resistance, thereby identifying new biomarkers and therapeutic vulnerabilities.

Technology development

We work closely with bioengineers to develop novel microfluidic technologies to enable complex molecular analyses of cancers.

Our team

CTC-chips (and counting)
Coffee cups (at least)
Patient Samples (at least)
Publications

our collaborators

Daniel Haber, MD, PhD
Director, MGH Cancer Center
Richard Lee, MD, PhD
Medical Oncologist, MGH Cancer Center
Jason Efstathiou, MD, DPhil
Radiation Oncologist, MGH
Shyamala Maheswaran, PhD
Biologist, MGH Cancer Center
Mehmet Toner, PhD
Engineer, MGH
David Ting, MD
Physician Scientist, MGH Cancer Center
Douglas Dahl, MD
Urologist, MGH
Adam Feldman, MD, MPH
Urologist, MGH
Henning Willers, MD
Radiation Oncologist, MGH
Shannon Stott, PhD
Bioengineer, MGH Cancer Center
Phil Saylor, MD
Medical Oncologist, MGH Cancer Center
Chin-Lee Wu, MD, PhD
Pathologist, MGH
Matthew Smith, MD, PhD
Medical Oncologist, MGH Cancer Center
Kent Mouw, MD, PhD
Physician Scientist, DFCI and BWH

Latest news

See all our news

Where are we located?

Contact Information